About BioConsult4.0

As the 21st century is unfolding, biomedical research is entering a new era. The design of CRISP-Cas9 and other gene-editing technologies is driving the development of cell and gene therapies for rare diseases and cancers. In addition, artificial intelligence (AI) revolutionises medical diagnostic and drug design, while 3D printing dramatically changes manufacturing far beyond the biopharmaceutical sector. 

However, it is not always easy for ​researchers in small structures to carry their research efforts while keeping up with the fast pace of scientific discoveries, technological innovation, and new regulations introduced by regulatory bodies (EMA/FDA). 

Our goal at BioConsult4.0 is to help small startups, academic labs, and research institutes grasp these innovations' promises by assisting them in navigating their complexity and regulatory environments to advance their preclinical and clinical research. ​ ​